Liver Elastography in Obese Patients: Why Blind Systems Fail and How Guided Acquisition Solves It
Australia's MAFLD patient population is predominantly high-BMI. Blind VCTE fails 20–25% of these patients with the standard M probe. Here is why — and how guided TE addresses the root cause.
The Australian Patient Profile: Why This Matters More Here
Australia's MAFLD and MASLD patient population is predominantly metabolically driven — overweight or obese, with type 2 diabetes or metabolic syndrome. The obesity rate in Australia is approximately 31%, with significantly higher rates in specific communities, regions, and age groups. The patient most likely to need liver fibrosis staging is also the patient most likely to return an unreliable or failed result on blind VCTE.
This is not a marginal problem. In a high-volume GP practice where 30–40% of patients have a BMI >30, the practical failure rate for blind VCTE in that practice's MAFLD cohort may approach 20% or higher — meaning 1 in 5 patients leaves without a usable result.
Why Blind VCTE Fails in High-BMI Patients: The Physics
VCTE uses a mechanical piston generating a shear wave at 50 Hz. The wave must propagate through subcutaneous tissue and reach the liver before the velocity measurement is taken. In high-BMI patients:
- Increased skin-to-liver distance means the shear wave attenuates more before reaching the measurement window
- Narrowed intercostal spaces from subcutaneous fat reduce the available acoustic window
- No real-time imaging means the operator cannot see whether the probe is positioned in a valid measurement window — they are acquiring blindly and hoping the IQR/M post-hoc check confirms consistency
The XL probe partially addresses point 1 by operating at a lower frequency for deeper penetration. It does not address points 2 or 3.
How Guided TE Addresses the Root Cause
Guided transient elastography uses the same mechanical shear wave principle as standard TE, but adds real-time B-mode imaging from the same probe. The operator sees the liver during the measurement. They can:
- Identify the optimal intercostal window that provides a clear acoustic path
- Position the measurement ROI in appropriate liver parenchyma away from vessels and bile ducts
- Confirm the shear wave is propagating correctly through liver tissue via real-time propagation maps
- Use a single universal wideband probe that works across all patient BMI ranges — no probe change or additional purchase required
Clinical Evidence: Failure Rate Comparison
| Patient Group | VCTE M Probe | VCTE XL Probe | Guided TE (iLivTouch) |
|---|---|---|---|
| BMI <25 | ~2–3% failure | Not indicated | ~2–3% failure |
| BMI 25–30 | ~8–10% failure | Not typically required | ~3–5% failure |
| BMI >30 | 20–25% failure | ~10–15% failure | ~5–7% failure |
| BMI >35 (severe obesity) | ~30–40% failure | ~15–20% failure | ~6–10% failure |
| Overall CLD population | ~11.6% failure | Variable | ~5.16% failure |
Approximate values based on published CLD cohort studies including Sjöman et al. and VCTE manufacturer data. Values vary by study population and operator experience.
Frequently Asked Questions
Why does FibroScan fail more often in obese patients?
FibroScan (VCTE) uses a blind mechanical piston without real-time ultrasound imaging. In obese patients, the increased skin-to-liver distance, narrowed intercostal spaces, and increased subcutaneous fat impede shear wave propagation and make accurate probe positioning without imaging guidance significantly more difficult. The standard M probe has a reported failure rate of 20–25% in patients with BMI >30.
Does the FibroScan XL probe solve the obesity problem?
The XL probe improves success rates in patients with high BMI compared to the M probe, reducing but not eliminating failure. The XL probe operates at a lower frequency to penetrate deeper tissue, but it still cannot visualise the liver during acquisition. Failure rates with the XL probe in very obese patients (BMI >40) remain clinically significant. The XL probe is also an additional capital purchase not included in the base FibroScan price.
How does guided TE perform better in obese patients?
Guided transient elastography uses real-time B-mode ultrasound imaging during the measurement. The operator can see the liver, identify the optimal measurement window (avoiding ribs, vessels, and subcutaneous fat), and confirm probe positioning before acquiring the shear wave. This visual guidance addresses the root cause of high-BMI failure — inability to confirm where the measurement is being taken — rather than compensating for it with a different probe.
See guided acquisition in your high-BMI patient cohort
Request a demonstration with your own patient mix — including high-BMI cases where blind VCTE has previously failed.
Request demonstration